Highly Traded Stock: Novavax, Inc. (NVAX)

Novavax, Inc. (NVAX) stock price distance from twenty day simple moving average slumped at -25.87% while its distance from fifty day simple moving average declined -36.36% along with -72.68% below distance from two hundred simple moving averages. (NVAX) has a trading volume of 5.75 Million shares, with an average trading volume of 4840 shares - with shares dropping to a 52 week low of $0.73, and the company's shares hitting a 52 week high of $ 8.49. The market capitalization of the company is at $1.04 Billion. RSI oscillates between zero and 100. Usually the RSI is considered overbought when above 70 and oversold when less than 30. Piermont Capital Management Inc. increased its stake in shares of Novavax by 9.2% in the third quarter. 4,490,051 shares of the stock traded hands. The average 12-month price objective among brokers that have updated their coverage on the stock in the previous year is $5.61. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. During the same period past year, the firm earned ($0.29) earnings per share.

Several other institutional investors have also bought and sold shares of the company. Analysts play a useful role in our capital markets. Investors measure stock performance on the basis of a company's earnings power. The analysts estimated mean EPS at 0.09 while the high and low EPS estimate stand at 0.11 and 0.08 respectively.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Novavax, Inc. the EPS stands at -0.21 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.23, suggesting the stock exceeded the analysts' expectations. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02.

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise.

Similarly, the company's last 5 years high P/E ratio is 262.25 and low P/E is 7.77, whereas, the industry's and sector's high P/E for the past year is 39.37 and 42.39 respectively and low P/E ratio for the last 5 years is 15.22 for the industry and 26.5 for the Sector.

5 number of analysts have estimated the sales of the company for the quarter ending April 25, 2017, analysts estimated mean sale target of 3144.72 million while high and low sale targets are estimated at 3208.62 million and 3024.26 million respectively.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of SUPERVALU Inc.

Moving average is significant analytical tool used to discover current price trends and the possibility for a change in an established trend.

The Stock has Weekly volatility of 7.77% and monthly volatility of 8.92%. There are advantages to using a moving average in your trading, as well options on what type of moving average to use. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. The stock's price moved up its 200-day moving average of $53.43. Recently, investment analysts covering the stock have updated the mean rating to 2. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The Return on Equity ratio of Novavax, Inc.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Moreover, Wedbush issued Downgrade rating for the stock on 16-Sep-16. Ladenburg Thalmann Financial Services reissued a "neutral" rating on shares of Novavax in a report on Wednesday, March 1st.

09/16/2016 - Novavax, Inc. was downgraded to " by analysts at JP Morgan.